title: CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.
abstract: PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.
authors.affiliation: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Nan
authors.initials: N
authors.lastname: Chen
authors.affiliation: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Aurore
authors.initials: A
authors.lastname: Morello
authors.affiliation: Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA.
authors.forename: Zachary
authors.initials: Z
authors.lastname: Tano
authors.affiliation: Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Prasad S
authors.initials: PS
authors.lastname: Adusumilli
keywords: Adoptive T-cell therapy; PD-1 blockade; breast cancer; immunosuppression; lung cancer; mesothelioma; tumor microenvironment